This meta-analysis of four RCTs evaluating GLP-1 receptor agonists in individuals with T2D demonstrates consistent effects on several cardiorenal outcomes, irrespective of baseline SGLT2i use. Here, GLP1R is linked to type 2 diabetes mellitus.